Acromegaly Epidemiology

Key Highlights

• Acromegaly is a rare hormonal disorder characterized by excessive production of growth hormone (GH) in the pituitary gland, a small gland located at the base of the brain. This overproduction of GH is most commonly caused by a non-cancerous tumor, known as an adenoma, in the pituitary gland. The condition primarily affects adults between the ages of 30 and 50, but it can develop at any age.
• Along with the physical changes, acromegaly can cause various health issues. Internal organs, such as the heart and respiratory system, may be affected, leading to cardiovascular problems and respiratory difficulties. Joint pain, arthritis, and carpal tunnel syndrome are common manifestations of the condition.
• Diagnosis is established through blood tests to measure GH and insulin-like growth factor 1 (IGF-1) levels, typically elevated in individuals with acromegaly. Imaging tests, like MRI or CT scans, locate pituitary tumors and determine their size.
• Regarding the epidemiology of acromegaly, in 2022, it was found that the United States accounted for ~47% of the total diagnosed prevelant cases of acromegaly in the 7MM.
• Among the EU4 countries, the least number of diagnosed prevalent cases of acromegaly were found in Spain, i.e., ~3,000 cases in the year 2022. These cases are expected to increase by 2034.
• In the current scenario, there is no well-defined standard of care for treating acromegaly patients. Also, there is no cure for the disease; the currently available medications only relieve symptoms, and patients cannot achieve a biochemical response

DelveInsight’s “Acromegaly – Epidemiology Forecast – 2034” report delivers an in-depth understanding of the Acromegaly, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2021-2034

Acromegaly Understanding and Diagnostic Algorithm

Acromegaly Overview

Acromegaly is a rare, slowly progressive, acquired disorder that affects adults. The pituitary gland produces too much growth hormone (GH). The pituitary gland is a small gland located near the base of the skull that stores several hormones and releases them into the bloodstream as needed by the body.

Further details related to overview are provided in the report…

Acromegaly Diagnosis

Screening is recommended for all patients presenting with clinical features of acromegaly (such as mass tumor effects, systemic effects of GH/IGF-1 excess, cardiovascular and metabolic features, respiratory and bone/joint manifestations, and/or other endocrine consequences). However, screening may also be considered in patients with several medical conditions associated with acromegaly, such as type 2 diabetes mellitus, carpal tunnel syndrome, debilitating arthritis, hypertension, and sleep apnea. Biochemical screening is the first step for an acromegaly diagnosis.

Further details related to diagnosis are provided in the report…

Acromegaly Epidemiology

The Acromegaly epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Acromegaly, Tumor Origin-specific Cases of Acromegaly, Gender-specific Cases of Acromegaly and Tumor Size-specific Cases of Acromegaly in the 7MM covering the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2021 to 2034.

• The United States accounted for ~27,000 diagnosed prevalent cases of acromegaly in 2022, which is projected to increase during the forecast period (2025-2034).
• The total diagnosed prevalent cases of acromegaly in EU4 and the UK were ~21,000 in 2022. The cases will increase during the forecast period (2025-2034).
• The total diagnosed prevalent cases of acromegaly in Japan were ~10,000 in 2022.
• The United Kingdom accounted for the highest number of diagnosed prevalent cases in EU4 and the UK, which were ~10% of the total diagnosed prevalent cases in the 7MM

Scope of the Report

• The report covers a segment of key events, an executive summary, and a descriptive overview of Acromegaly, explaining its etiology, risk factors, pathophysiology, and diagnosis.
• Comprehensive insight into the country-wise epidemiology segments and forecasts, the future growth potential of diagnosis rate, and insights on disease progression have been provided.
• Patient stratification based on tumor origin, gender and size is an inclusion
• A detailed review of current challenges in establishing diagnosis

Acromegaly Report Insights

• Acromegaly Patient Population
• Tumor Origin-specific, Gender-specific And Tumor Size-specific Distribution in Acromegaly
• Country-wise Epidemiology Distribution

Acromegaly Report Key Strengths

• 10 year Forecast
• The 7MM Coverage
• Acromegaly Epidemiology Segmentation

Acromegaly Report Assessment

• Epidemiology Segmentation
• Current Diagnostic Practices

Key Questions

Epidemiology Insights

• What are the disease risks, burdens, and unmet needs of Acromegaly? What will be the growth opportunities across the 7MM with respect to the patient population of Acromegaly?
• What is the historical and forecasted Acromegaly patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• Which gender is the largest contributor to the Acromegaly patient pool?
• Which tumor size has the most number of cases of Acromegaly in the 7MM?

Reasons to Buy

• Insights on disease burden, details regarding diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the change in Acromegaly cases in varying geographies over the coming years.
• Detailed overview on tumor origin-specific, gender-specific and tumor size-specific cases of Acromegaly is included.
• To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis and insights on the treatment-eligible patient pool.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.